Introduction
Breast cancer is one of the major health problem that affect 1676633 human worldwide. With this number, breast cancer is the leading cancer diagnosed in the women and is second only to lung cancer in terms of total fatalities [1] . Survival of breast cancer patients have increased tremendously over the last few decades. However, this applies only if the breast cancer is diagnosed at an early stage and is limited to the primary organ. Once breast cancer metastasizes to other organs, the therapeutic options are very limited and the success rate of managing such patients in clinics is dismal. Breast cancer is driven by progressive genetic changes and epigenetic abnormalities [2] . It includes changed patterns of histone modification, with resultant remodeling of structure of chromatin and hypo-and hypermethylation of DNA. These changes cause deregulation of the transcription activity of many genes. Epigenetic regulation is critical for normal growth and development and provides a layer of transcriptional control. Therefore, the evaluation of the cancer-specific methylation pattern changes in the promoter regions has an important potential to improve an early detection of cancer and prediction of therapy and prognostic response. The aim of this study was to compare the relationship between DNA methylation levels of 11 genes participated on growth signal transferring (APC, ESR1, PGR B, RASSF1A, SYK and SOCS1) and metastasis formation (ADAM23, CXCL12, CDH1, TIMP3 and BRMS1). Since the selected genes contain CpG islands in promotor area they are epigenetically regulated with a high probability. Moreover, in breast carcinomas the different levels of methylation of the genes concerned were observed, suggesting different reduction rates of protein products synthesis.
Methods
A total of 185 paraffin-embedded tumor tissue samples from non-familiar patients with primary breast cancer and 55 healthy controls as well as plasma and peripheral blood cells have been analysed by using highly quantitative method of pyrosequencing. Tumors obtained from Slovak patients were staged and graded according to the current WHO classification for breast neoplasms. DNA from paraffin-embedded tumor tissues was isolated by the MagneSil Genomic, Fixed Tissue System (Promega, Madison, WI), from peripheral blood cell by using a FlexiGene DNA kit (Qiagen, Hilden, Germany) and from plasma samples by using a QIAamp DSP Virus Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. DNA methylation in 11 genes (APC, ESR1, PGR B, RASSF1A, SYK, SOCS1, ADAM23, CXCL12, CDH1, TIMP3, BRMS1) containing CpG islands in promoter region was evaluated after the sodium bisulfite-treatment of isolated DNA [3, 4, 5, 6] . CpG islands in the promoter area flanking the transcription start site at 5'UTR were selected for each gene. Five to eight CpG sites were studied for each particular CpG island. In ESR1gene the methylation status for two regions in the promoter A and in the first exon was evaluated, completely 14 CpG sites.
Pyrosequencing assays primer sequences and PCR conditions were taken from [7] . For ESR1 gene was designed additional set of the oligonucleotides for PCR amplification and pyrosequencing of the promoter A using PyroMark Assay Design software 2.0 (Qiagen, Hilden, Germany). PCR primers for ESR1 promoter A region 2: F primer -GTTGGAGGTTAGGGAGTTTAGG, R primer -biotin-TCTAACCCCCACCCTACCCC. Sequence for pyrosequencing primer is GGGAGTTTAGGAGTTGG. PCR product size is 120bp and it is analysed other 9 CpG sites.
A total 1 μg of peripheral blood cells DNA was bisulfite converted using the CpGenome DNA Modification Kit (Chemicon, 150 Billerica, MA). Cell free DNAs from plasma (2 μg) and tumor DNA (2 μg) were modified according to the protocol of EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). PCR reactions were provided using the PyroMark PCR Kit (Qiagen, Hilden, Germany) according to the manual instructions with several modifications [7] . PCR conditions for ESR1 promoter A region 2 were modified for final PCR primer concentrations to 0.28 μM. The annealing temperature was modified to 58°C for 30 seconds (Table 1) . Pyrosequencing was carried out using a PyroMark Q24 system and the PyroGold Reagent Kit (Qiagen, Hilden, Germany). The results of the analyses were evaluated using the PyroMark Q24 2.0.6. software (Qiagen, Hilden, Germany). Methylation data are presented as the percentage of average methylation in all CpG sites observed and were calculated for each sample and each gene. Protein expression in malignant breast tissues was detected with specific antibodies against 11 corresponding proteins. Statistical analysis was performed by SPSS statistics 15.0 software. PCR reactions contained 2 μl sodium bisulfite-treated DNA for peripheral blood cells and 4 μl sodium bisulfite-treated DNA for cfDNA and paraffinembedded tumour tissues.
Results and Discussion
DNA hypermethylation of tumor suppressor genes is tumor-specific process and could be used for tumor cells recognition. Bisulfite pyrosequencing was used to investigate DNA methylation profiles in formalin fixed paraffin-embedded tissues, blood cells and plasma samples in 185 patients with primary breast cancer.
Clinical and histopathological characteristics of patients are summarized in table 2. We observed higher methylation status in 4 genes (RASSF1A, APC, CXCL12 and ADAM23) from 11 genes evaluated in tumors. Average DNA methylation levels in tumor tissue were as follows: 38.57% ± 25.76 for RASSF1A gene, 23.73% ± 22.38 for APC gene, 9.36% ± 10.58 for the gene ADAM23 and 11.83% ± 12.01 for the gene CXCL12.The highest promoter methylation level was 88% detected in both RASSF1A and APC genes (Table  3) . One third of all breast cancer patient display ER negative phenotype and to date it is still not clear if chromosomal alteration or mutations might be responsible for this phenotype. Moreover, changes in the ER tumor expression status were observed, when the ER positive tumors became ER negative during the patient treatment. Hypermethylation in the promoter region of the gene ESR1 represents one of the possible mechanisms for loss of ESR1 gene expression since methylation represents a reversible and dynamic process. The expressions of ER and PR receptors need to be monitored to identify patients that will positively respond to hormonal antiestogen treatment [8, 9] .
In our results, the values of ESR1 gene methylation in paraffin embedded tumor tissue were relatively low and ranged from 1-31 % among the individual patients (Figure 1 ) with average value 8.89 % ± 4.00. Average value of methylation measured in patients peripheral blood lymphocytes is 4.36 % ± 1.31 (range of 1-9 %) which is just slightly higher when compared to healthy controls 3.33 ± 0.90 % (range 2-6 %). In similar study reported by other authors the aberrant DNA methylation was not detected in gene ESR1 [4, 9] . In contrast to the authors who have demonstrated significant levels of DNA methylation in gene ESR1 [11, 12, 13] , we have analyzed the higher number of CpG dinucleotides in the ESR1 gene and we used pyrosequencing as more sensitive quantitative method for analyzing methylation of specific CpG dinucleotides. The average values of methylation in studied tumor samples of the 131 ER positive and 29 ER negative patients were 8.76 % ± 4.065 (range 1-31 %) and 9 % ± 3.625 (range 2-16 %), respectively. These methylation levels are nearly identical, and they are most likely not responsible for partial or complete inhibition of gene expression. In literature, complete absence of ADAM23 tumor suppressor gene expression was observed for breast cancer patients with the DNA methylation levels in range of 40-60 % [14] , and for colorectal cancer patients in range of 70-90 % [15] . Based on these findings we can conclude that low level of ESR1 gene methylation we identified in analyzed tumor samples is not responsible for the lack of ER expression. The relationship between ESR1 promoter methylation and ER expression was statistically not significant with P = 0.464. ER expression in the tumor ranged from 0-100 %. It is currently estimated that the immunohistochemical determination of estrogen receptor expression is determined incorrect (false positive or false negative) in up to 20 % of cases a worldwide. The subjective evaluation of positive stained cells and the staining intensity of the signal, and also definition of thresholds for ER positive and negative tumors could be the reasons of this mistake. Tumors were considered to be positive tumors in case of at least 1 % of the tumor tissue cells shown immunoreactivity.
Some studies indicate that also other mechanisms regulating ESR1 gene expression may be involved, such as aberrant miRNA regulation and posttranscriptional modifications of histones [16] . MicroRNAs are small noncoding RNAs that suppress post-transcriptional gene expression by pairing with the 3 'UTR of target mRNAs. Several studies have demonstrated a correlation between microRNA-212/222 and ER expression. Over-expression of microRNA-212/222 in ER positive breast tumors showed a suppression of expression of ER and other proteins [17] . Also reduction of the histone deacetylase HDAC1 level in advanced stage cancer associated with negative expression of ER has been described in regard to the status of estrogen receptors of breast carcinomas [18] .
The data obtained for the progesterone receptor PR were as follows: average values of methylation in tumor tissue 7.26 ± 6.51% (range 1-48%), in peripheral blood lymphocytes of patients 5.19% ± 1.67 (range 0-13 %) and in healthy controls, 4.45% ± 1.25 (range 1-7%). Although the significant correlation between the level of methylation and expression of progesterone receptor was found in tumor of the patients (P = 0.020), the mean DNA methylation values in tumor and peripheral blood cell in PGR B are very similar and therefore the low DNA methylation of PGR B gene could not initiate inhibition of relevant protein expression. It was demonstrated that expression of the two promoters in PGR B gene is induced by the ER in function of transcription factor [19] . It suggests that in ER negative patients, the progesterone receptor should not be expressed, independently on methylation status.
In our study the variable expression profiles in all analyzed genes ranging from negative expression to high expression were found, but no relationship with biological significance between DNA methylation and protein expression was demonstrated. 
Conclusion
Breast cancer is a heterogeneous disease for which alterations in DNA methylation patterns have been shown to be of biological and clinical importance. We can conclude that the quantitative analyses of tumor DNA methylation in any of RASSF1A, ADAM23, CXCL12 and APC genes could have prognostic potential. Surprisingly, the determination of methylation in genes ESR1 and PGR B encoded hormonal receptors have not a relevant for prognosis or development of the disease.
Identification of early epigenetic changes in breast cancer might give valuable markers for early detection and contribute to the understanding of how these changes affect the progression of the disease and prognosis for the patient.
